Bemiparin sodium
As of the edition of 20 October 2026, Bemiparin sodium is an oligosaccharide: marketed; acts on SERPINC1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Oligosaccharide
- Brand name
- Entervit
- Approvals on record
- 17 in 17 regions
- Holder of the most recent approval
- Gineladius, S.L.; 2 holders in all
- Registered trials
- 3, 0 stopped early
- Disease areas
- Heart and blood vessels; Infections; Lungs and airways; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SERPINC1 | Antithrombin-III | P01008 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 2 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Berlin-Chemie AG Menarini | Lead sponsor of trials | 2013 to now |